Literature DB >> 26069484

Evaluation of pullulan-functionalized doxorubicin nanoparticles for asialoglycoprotein receptor-mediated uptake in Hep G2 cell line.

Swati A Guhagarkar1, Sharmila B Majee2, Abdul Samad3, Padma V Devarajan1.   

Abstract

The present study discusses evaluation of pullulan-functionalized doxorubicin nanoparticles for asialoglycoprotein receptor-mediated uptake in the Hep G2 cell line. Doxorubicin hydrochloride (DOX) nanoparticles using polymers of different hydrophobic character, polyethylene sebacate (hydrophobic) and poly (lactic-co-glycolic acid) (intermediate hydrophobicity) with high entrapment efficiency and particle size were prepared by modified nanoprecipitation, using Gantrez AN 119 as complexing agent. Nanoparticles of Gantrez AN 119 were also prepared to represent a hydrophilic polymer. Cell uptake of DOX nanoparticles was found to be comparable to DOX solution irrespective of DOX concentration, nanoparticles size, and pullulan concentration. Furthermore, uptake of nanoparticles functionalized with or without pullulan prepared with polymers of different hydrophobic character revealed comparable uptake. Comparable uptake of DOX solution and DOX nanoparticles functionalized with or without pullulan suggest extracellular release of DOX as the mechanism of uptake from the nanoparticles. In vivo evaluation in hepatic cancer model is therefore essential to confirm the role of pullulan as asialoglycoprotein receptors ligand.

Entities:  

Keywords:  Asialoglycoprotein receptor; Doxorubicin; Hep G2 cells; Polyethylene sebacate; Pullulan

Year:  2011        PMID: 26069484      PMCID: PMC4451860          DOI: 10.1007/s12645-011-0012-x

Source DB:  PubMed          Journal:  Cancer Nanotechnol        ISSN: 1868-6958


  35 in total

1.  Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine.

Authors:  P J Julyan; L W Seymour; D R Ferry; S Daryani; C M Boivin; J Doran; M David; D Anderson; C Christodoulou; A M Young; S Hesslewood; D J Kerr
Journal:  J Control Release       Date:  1999-02-22       Impact factor: 9.776

2.  Pharmacokinetic analysis of hepatic uptake of galactosylated bovine serum albumin in a perfused rat liver.

Authors:  K Ogawara; M Nishikawa; Y Takakura; M Hashida
Journal:  J Control Release       Date:  1998-01-02       Impact factor: 9.776

3.  Determination of the upper size limit for uptake and processing of ligands by the asialoglycoprotein receptor on hepatocytes in vitro and in vivo.

Authors:  P C Rensen; L A Sliedregt; M Ferns; E Kieviet; S M van Rossenberg; S H van Leeuwen; T J van Berkel; E A Biessen
Journal:  J Biol Chem       Date:  2001-07-30       Impact factor: 5.157

4.  Evidence for receptor-mediated hepatic uptake of pullulan in rats.

Authors:  Y Kaneo; T Tanaka; T Nakano; Y Yamaguchi
Journal:  J Control Release       Date:  2001-02-23       Impact factor: 9.776

Review 5.  Targeting hepatocytes for drug and gene delivery: emerging novel approaches and applications.

Authors:  Jian Wu; Michael H Nantz; Mark A Zern
Journal:  Front Biosci       Date:  2002-03-01

6.  Doxorubicin coupled to lactosaminated albumin: Effects on rats with liver fibrosis and cirrhosis.

Authors:  G Di Stefano; L Fiume; M Domenicali; C Busi; P Chieco; F Kratz; M Lanza; A Mattioli; M Pariali; M Bernardi
Journal:  Dig Liver Dis       Date:  2006-04-03       Impact factor: 4.088

7.  Enhanced hepatocyte uptake and liver targeting of methotrexate using galactosylated albumin as a carrier.

Authors:  J H Han; Y K Oh; D S Kim; C K Kim
Journal:  Int J Pharm       Date:  1999-10-15       Impact factor: 5.875

8.  Uptake characteristics of galactosylated emulsion by HepG2 hepatoma cells.

Authors:  Chittima Managit; Shigeru Kawakami; Fumiyoshi Yamashita; Mitsuru Hashida
Journal:  Int J Pharm       Date:  2005-09-14       Impact factor: 5.875

9.  Targeting of soybean-derived sterylglucoside liposomes to liver tumors in rat and mouse models.

Authors:  K Shimizu; X R Qi; Y Maitani; M Yoshii; K Kawano; K Takayama; T Nagai
Journal:  Biol Pharm Bull       Date:  1998-07       Impact factor: 2.233

10.  Binding and endocytosis of cluster glycosides by rabbit hepatocytes. Evidence for a short-circuit pathway that does not lead to degradation.

Authors:  D T Connolly; R R Townsend; K Kawaguchi; W R Bell; Y C Lee
Journal:  J Biol Chem       Date:  1982-01-25       Impact factor: 5.157

View more
  3 in total

1.  Receptor-mediated hepatocyte-targeted delivery of primaquine phosphate nanocarboplex using a carbohydrate ligand.

Authors:  Vishvesh M Joshi; Padma V Devarajan
Journal:  Drug Deliv Transl Res       Date:  2014-08       Impact factor: 4.617

2.  Modifying glycyrrhetinic acid liposomes with liver-targeting ligand of galactosylated derivative: preparation and evaluations.

Authors:  Jing Chen; Yuchao Chen; Yi Cheng; Youheng Gao; Pinjing Zheng; Chuangnan Li; Yidan Tong; Zhao Li; Wenhui Luo; Zhao Chen
Journal:  Oncotarget       Date:  2017-10-27

3.  Targeted and synergistic therapy for hepatocellular carcinoma: monosaccharide modified lipid nanoparticles for the co-delivery of doxorubicin and sorafenib.

Authors:  Wendu Duan; Yan Liu
Journal:  Drug Des Devel Ther       Date:  2018-07-11       Impact factor: 4.162

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.